NASDAQ:CARM Carisma Therapeutics (CARM) Stock Price, News & Analysis $0.0025 0.00 (0.00%) As of 08/11/2026 10:29 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Carisma Therapeutics Stock (NASDAQ:CARM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Carisma Therapeutics alerts:Sign Up Key Stats Today's Range$0.0025▼$0.002550-Day Range$0.00▼$0.0252-Week Range$0.00▼$0.56Volume577 shsAverage Volume68,411 shsMarket Capitalization$104.61 thousandP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Carisma Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells. The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors. In parallel, Carisma is advancing CT-381, an engineered myeloid cell therapy designed to modulate inflammatory and autoimmune conditions. Preclinical data have demonstrated robust antigen-dependent activation, tumor penetration and anti-tumor efficacy in multiple models, supporting the progression of these programs toward their first clinical studies. Carisma’s interdisciplinary team combines expertise in myeloid biology, genetic engineering and translational medicine. The company partners with leading academic institutions and specialized contract development and manufacturing organizations to establish scalable, GMP-compliant processes for its cell therapies. By uniting macrophage biology with CAR engineering, Carisma Therapeutics seeks to create a novel class of treatments with broad applications across oncology and immune-mediated diseases.AI Generated. May Contain Errors. Read More Carisma Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreCARM MarketRank™: Carisma Therapeutics scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingCarisma Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCarisma Therapeutics has received no research coverage in the past 90 days.Read more about Carisma Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.32) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is 0.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 268.36. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CARM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows6 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of Carisma Therapeutics is held by insiders.Percentage Held by Institutions44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Carisma Therapeutics' insider trading history. Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CARM Stock News HeadlinesCarmila: 2025 Annual ResultsFebruary 18, 2026 | businesswire.comCarisma Therapeutics announces Nasdaq delisting, SEC deregistrationDecember 6, 2025 | msn.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.August 12 at 1:00 AM | Priority Gold (Ad)Carisma Announces Delisting from Nasdaq and SEC DeregistrationDecember 5, 2025 | prnewswire.comCarisma Therapeutics Announces Executive Terminations and Wind-DownOctober 17, 2025 | msn.comCarisma Therapeutics stock plunges after Nasdaq delisting noticeOctober 10, 2025 | investing.comCarisma Therapeutics Faces Nasdaq Delisting and Trading SuspensionOctober 9, 2025 | tipranks.comCarisma Therapeutics Amends Agreement with ModernaSeptember 18, 2025 | tipranks.comSee More Headlines CARM Stock Analysis - Frequently Asked Questions How have CARM shares performed this year? Carisma Therapeutics' stock was trading at $0.0440 at the start of the year. Since then, CARM shares have decreased by 94.3% and is now trading at $0.0025. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics Inc. (NASDAQ:CARM) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.05. The firm had revenue of $3.65 million for the quarter, compared to the consensus estimate of $2.47 million. When did Carisma Therapeutics IPO? Carisma Therapeutics (CARM) raised $70 million in an IPO on Thursday, February 6th 2014. The company issued 5,000,000 shares at $13.00-$15.00 per share. How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Carisma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/13/2025Today8/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CARM CIK1485003 Webwww.sesenbio.com Phone617-444-8550Fax617-858-0911Employees20Year Founded2008Profitability EPS (Trailing Twelve Months)$0.73 Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.48 million Net Margins-254.28% Pretax Margin-458.60% Return on EquityN/A Return on Assets-192.17% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual Sales$10.77 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book0.00Miscellaneous Outstanding Shares41,845,000Free Float38,905,000Market Cap$104.61 thousand OptionableNo Data Beta-9.09 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:CARM) was last updated on 8/12/2026 by MarketBeat.com Staff. From Our Partners7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredOne trade you can make to move the needle todayEric Fry has been analyzing markets since the 1980s, working as a professional portfolio manager for over a de...InvestorPlace | SponsoredThe trading strategy that works BECAUSE you have a lifeTim Sykes built a trading strategy for people who can't watch charts from 9:30 to 4:00 every day. It's not ...Tim Sykes | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
